The online version of this article (https://doi.org/10.1007/s00125-018-4739-3) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
Joachim Gæde, Jens Oellgaard and Rikke Ibsen contributed equally to this work.
Long-term follow-up of the Steno-2 study demonstrated that intensified multifactorial intervention increased median lifespan by 7.9 years and delayed incident cardiovascular disease by a median of 8.1 years compared with conventional multifactorial intervention during 21.2 years of follow-up. In this post hoc analysis of data from the Steno-2 study, we aimed to study the difference in direct medical costs associated with conventional vs intensified treatment.
In 1993, 160 Danish individuals with type 2 diabetes and microalbuminuria were randomised to conventional or intensified multifactorial target-driven intervention for 7.8 years. Information on direct healthcare costs was retrieved from health registries, and the costs in the two groups of participants were compared by bootstrap t test analysis.
Over 21.2 years of follow-up, there was no difference in total direct medical costs between the intensified treatment group, €12,126,900, and the conventional treatment group, €11,181,700 (p = 0.48). The mean cost per person-year during 1996–2014 was significantly lower in the intensified treatment group (€8725 in the intensive group and €10,091 in the conventional group, p = 0.045). The main driver of this difference was reduced costs associated with inpatient admissions related to cardiovascular disease (p = 0.0024).
Over a follow-up period of 21.2 years, we found no difference in total costs and reduced cost per person-year associated with intensified multifactorial treatment for 7.8 years compared with conventional multifactorial treatment. Considering the substantial gain in life-years and health benefits achieved with intensified treatment, we conclude that intensified multifaceted intervention in high-risk individuals with type 2 diabetes seems to be highly feasible when balancing healthcare costs and treatment benefits in a Danish healthcare setting.
ESM (PDF 490 kb)125_2018_4739_MOESM1_ESM.pdf
Gæde P, Oellgaard J, Carstensen B et al (2016) Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59:2298–2307. https://doi.org/10.1007/s00125-016-4065-6 CrossRefPubMedPubMedCentral
Oellgaard J, Gaede P, Rossing P, Persson F, Parving HH, Pedersen O (2017) Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int 91:982–988. https://doi.org/10.1016/j.kint.2016.11.023 CrossRefPubMed
Oellgaard J, Gaede P, Rossing P et al (2018) Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia 61:1724–1733. https://doi.org/10.1007/s00125-018-4642-y CrossRefPubMedPubMedCentral
Gæde P, Vedel P, Parving HH, Pedersen O (1999) Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet (London, England) 353:617–622. https://doi.org/10.1016/S0140-6736(98)07368-1 CrossRef
Tunceli K, Bradley CJ, Nerenz D, Williams LK, Pladevall M, Elston Lafata J (2005) The impact of diabetes on employment and work productivity. Diabetes Care 28:2662–2667. https://doi.org/10.2337/diacare.28.11.2662 CrossRefPubMed
- A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study
- Springer Berlin Heidelberg
Clinical, Translational and Experimental Diabetes and Metabolism
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II